BSP. All communications with Regulatory Authorities concerning any Compound shall be the sole responsibility of BSP. Prometheus shall not, without the consent of BSP or unless so required by Applicable Law, correspond or communicate with the Regulatory Authority concerning any Compound, or otherwise take any action concerning any filings or communications with any applicable Regulatory Authorities in connection with the development or Commercialization of any Compound; provided that during the Term, Prometheus shall have the right to communicate with any Regulatory Authority regarding a Compound if such communication is necessary to comply with the terms of this Agreement or any Applicable Law and Prometheus shall promptly notify BSP of such communication unless prevented from doing so under Applicable Law. At BSP’s request, Prometheus will, consistent with the other terms of this Agreement, take Commercially Reasonable Efforts to co-operate with BSP in communicating (including attending meetings with Regulatory Authorities) with the Regulatory Authorities about any Assay, BSP Array or Diagnostic Product, when such communications are important in seeking Regulatory Approval of any Compound. [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
BSP. On November 30, 2000, BDSI entered into an agreement with Biotech Specialty Partners, LLC (“BSP”), then an emerging alliance of early stage biotechnology and specialty pharmaceutical companies. BSP to date has not distributed any pharmaceutical products. Under this agreement, BSP will serve as a nonexclusive distributor of BDSI’s products in consideration of a ten (10%) percent discount to the wholesale price, which BDSI’s board of directors has determined to be commercially reasonable. BSP has waived its rights under this agreement with respect to products which include the BEMA® technology. Xxxxxxx Capital Group is an equity owner of, and Xx. X’Xxxxxxx is a member of the management of, BSP. Confidential Treatment Requested by BioDelivery Sciences International, Inc. IRS Employer Identification No. 35-208985 Confidential treatment requested with respect to certain portions hereof denoted with “***” PERFECTION CERTIFICATE UPDATE SCHEDULE
BSP. No employee shall be allowed to enter or remove his/her name onto or from the database while the Field Service Team Supervisor/Coordinator is actively seeking personnel to fill a request for field team. The all volunteer rosters from each unit, that is shop or branch, whichever is applicable, will be called the “A” list. All employees in the bargaining unit may, at some time, be required to travel to accomplish the Facility’s support efforts and they will be placed on rosters at the branch level. These listings will be known as the “B” list. Any selection for field service teams will be in accordance with the terms of this article and the current Field Team SOP/6.2
BSP. Complete records of all field service team actions will be maintained for the duration of this Agreement by the supervisor of the Field Service Team Shop and will be made available to the appropriate Union representative. The “A” rosters will be provided once a
BSP. Procedures to select employees to fulfill work related travel requirements for situations that are outside of the normal day to day operations and differ from those described in Section 13 of this Article shall be discussed by the Parties in an attempt to reach mutual agreement. If mutual agreement is reached, such procedures will be described in a separate Memorandum of Agreement/Memorandum of Understanding. The Employer and the Union shall make such agreements available to bargaining unit employees via the Employer’s intranet or upon request by hard copy.
BSP. 16.1 BSP 16.11 BSP 16.12 BSP 16.13 BSP 16.14 BSP
BSP. On November 30, 2000, BDSI entered into an agreement with Biotech Specialty Partners, LLC (“BSP”), then an emerging alliance of early stage biotechnology and specialty pharmaceutical companies. BSP to date has not distributed any pharmaceutical products. Under this agreement, BSP will serve as a nonexclusive distributor of our products in consideration of a ten (10%) percent discount to the wholesale price, which BDSI’s board of directors has determined to be commercially reasonable. BSP has waived its rights under this agreement with respect to products which include the BEMA® technology. HCG is an equity owner of, and Xx. X’Xxxxxxx is a member of the management of, BSP.
BSP. Commencing upon the Effective Date until expiration of the BSP Option Term (and as extended pursuant to Section 5.1.3), or, following Celgene’s exercise of the Option for the BSP Program, for the period of time set forth in Section 5.1 of any then-applicable Development & Commercialization Agreement for the BSP Program, [***] and its Affiliates shall not, except as otherwise expressly permitted in Sections 5.2 and 5.4 of this Agreement: (a) [***], (b) [***], or (c) except as expressly permitted under Section 12.4 of this Agreement or Section 11.4 of any then-applicable Development & Commercialization Agreement, as applicable, [***].
BSP. How is the treatment efficiency related to the VAL? If remove the VAL, maintenance requirements would be significantly reduced. The result however may be that we need to increase reactor size? Would it be possible to install cheap solar panels to power some bulbs during evening hours to keep processes running and possibly reduce required reactor size? UV No anticipated issues
BSP. It seems OK. No major comments and concern here. No information about the required hours of sunlight and intensity. Both significantly varies during the year.
